ARWR
Arrowhead Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$59.90Close
$8.1BMarket cap
$37.85 – $89.5952-week range
Nov 24, 2026Next report
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 28 · weaker than 72% of stocks over 12 months
- Far from its high 33% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
33%
1wk
up 3.2%
price change
1mo
down 8.5%
price change
12-month return
up 42%
market up 11% ·
its own up 38%
F-score
—
— Not assessed
Altman Z
5.15
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
17.4×
price / book
Earnings yield
up 1.2%
EBIT / enterprise value
Cheaper than
25%
of the market · expensive
Revenue growth
up 23258%
year on year
EPS growth
—
latest quarter
Sales growth
up 171%
latest quarter · +257 pts
ROE
down 1%
return on equity
Free cash margin
up 19%
$156.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-1.9×
net cash
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- FCF turned positive ($-604M → $157M)
- Revenue reaccelerating (-99% then +23258%)
Trade setup
ATR%
4.2%
$2.51 a day · 2×ATR $54.88
RS
28 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.68
50 sessions
Implied move
—
no option chain · report Nov 24, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 9.1% over the year, from 124m to 136m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Last shock
Sep 15, 2026-12% in one session2.5× volumeno filing matched-15% since
Financials
- Net -0%
- Free cash 19%
- Cash
- Long-term debt
| FY2020Sep 30, 2020 | FY2021Sep 30, 2021 | FY2022Sep 30, 2022 | FY2023Sep 30, 2023 | FY2024Sep 30, 2024 | FY2025Sep 30, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M |
| Operating income | -$93.2M | -$149.0M | -$178.5M | -$205.0M | -$601.1M | $98.3M |
| Net income | -$84.6M | -$140.8M | -$176.1M | -$205.3M | -$599.5M | -$1.6M |
| Net margin | -96% | -102% | -72% | -85% | -16882% | -0% |
| Earnings per share | -$0.84 | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 |
| Free cash flow | -$107.8M | $147.7M | -$188.9M | -$330.6M | -$604.3M | $156.9M |
| Free cash margin | -122% | 107% | -78% | -137% | -17018% | 19% |
| Cash | $143.6M | $184.4M | $108.0M | $110.9M | $102.7M | $226.5M |
| Shareholders' equity | $461.8M | $408.8M | $398.5M | $271.3M | $185.4M | $466.1M |
| Shares outstanding | 102.38m | 104.33m | 105.96m | 107.31m | 124.38m | 135.70m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 5, 2026 | Quarterly ↗ | Dec 31, 2025 | 36d |
| Nov 25, 2025 | Annual ↗ | Sep 30, 2025 | 56d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Feb 10, 2025 | Quarterly ↗ | Dec 31, 2024 | 41d |
| Nov 26, 2024 | Annual ↗ | Sep 30, 2024 | 57d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 6, 2024 | Quarterly ↗ | Dec 31, 2023 | 37d |
| Nov 29, 2023 | Annual ↗ | Sep 30, 2023 | 60d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 4, 2026 | Results ↗ |
| Jun 16, 2026 | Director or officer change ↗ |
| May 7, 2026 | Results ↗ |
| Mar 20, 2026 | Shareholder vote ↗ |
| Feb 5, 2026 | Results ↗ |
| Jan 12, 2026 | Material agreement · New obligation ↗ |
| Jan 9, 2026 | Material agreement · Other events ↗ |
| Jan 6, 2026 | Regulation FD · Other events ↗ |
| Nov 25, 2025 | Results ↗ |
| Nov 18, 2025 | Other events ↗ |
| Sep 12, 2025 | Other events ↗ |
| Sep 11, 2025 | Other events ↗ |